QQQ   360.01 (+0.56%)
AAPL   171.84 (+0.67%)
MSFT   317.75 (+1.31%)
META   305.27 (+0.43%)
GOOGL   132.04 (-0.20%)
AMZN   127.64 (+1.32%)
TSLA   251.65 (+2.14%)
NVDA   437.51 (+1.54%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   103.66 (+0.88%)
T   14.92 (-0.60%)
F   12.58 (+0.16%)
MU   67.96 (+4.23%)
CGC   0.80 (-1.18%)
GE   110.76 (-1.41%)
DIS   80.74 (+0.76%)
AMC   8.00 (+2.70%)
PFE   32.81 (+2.24%)
PYPL   58.54 (+0.62%)
NFLX   377.09 (+0.19%)
QQQ   360.01 (+0.56%)
AAPL   171.84 (+0.67%)
MSFT   317.75 (+1.31%)
META   305.27 (+0.43%)
GOOGL   132.04 (-0.20%)
AMZN   127.64 (+1.32%)
TSLA   251.65 (+2.14%)
NVDA   437.51 (+1.54%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   103.66 (+0.88%)
T   14.92 (-0.60%)
F   12.58 (+0.16%)
MU   67.96 (+4.23%)
CGC   0.80 (-1.18%)
GE   110.76 (-1.41%)
DIS   80.74 (+0.76%)
AMC   8.00 (+2.70%)
PFE   32.81 (+2.24%)
PYPL   58.54 (+0.62%)
NFLX   377.09 (+0.19%)
QQQ   360.01 (+0.56%)
AAPL   171.84 (+0.67%)
MSFT   317.75 (+1.31%)
META   305.27 (+0.43%)
GOOGL   132.04 (-0.20%)
AMZN   127.64 (+1.32%)
TSLA   251.65 (+2.14%)
NVDA   437.51 (+1.54%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   103.66 (+0.88%)
T   14.92 (-0.60%)
F   12.58 (+0.16%)
MU   67.96 (+4.23%)
CGC   0.80 (-1.18%)
GE   110.76 (-1.41%)
DIS   80.74 (+0.76%)
AMC   8.00 (+2.70%)
PFE   32.81 (+2.24%)
PYPL   58.54 (+0.62%)
NFLX   377.09 (+0.19%)
QQQ   360.01 (+0.56%)
AAPL   171.84 (+0.67%)
MSFT   317.75 (+1.31%)
META   305.27 (+0.43%)
GOOGL   132.04 (-0.20%)
AMZN   127.64 (+1.32%)
TSLA   251.65 (+2.14%)
NVDA   437.51 (+1.54%)
NIO   9.05 (+1.57%)
BABA   87.00 (+1.71%)
AMD   103.66 (+0.88%)
T   14.92 (-0.60%)
F   12.58 (+0.16%)
MU   67.96 (+4.23%)
CGC   0.80 (-1.18%)
GE   110.76 (-1.41%)
DIS   80.74 (+0.76%)
AMC   8.00 (+2.70%)
PFE   32.81 (+2.24%)
PYPL   58.54 (+0.62%)
NFLX   377.09 (+0.19%)
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Forecast, Price & News

$31.62
-0.14 (-0.44%)
(As of 11:52 AM ET)
Compare
Today's Range
$31.42
$32.47
50-Day Range
$31.76
$43.37
52-Week Range
$31.13
$63.12
Volume
221,720 shs
Average Volume
986,319 shs
Market Capitalization
$2.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.18

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
152.4% Upside
$80.18 Price Target
Short Interest
Bearish
8.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.18mentions of Intellia Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$99,174 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.59) to ($6.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

261st out of 970 stocks

Diagnostic Substances Industry

5th out of 13 stocks


NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Price History

NTLA Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (NTLA)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Intellia Therapeutics (NASDAQ:NTLA) Sets New 52-Week Low at $32.44
Uranium Prices Surge as Nuclear Energy Becomes Key
Renewed interest in uranium and rising prices have created a favorable environment for new projects.
Intellia Therapeutics Inc NTLA Stock Quote
BMO Capital Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Uranium Prices Surge as Nuclear Energy Becomes Key
Renewed interest in uranium and rising prices have created a favorable environment for new projects.
RBC Capital Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Here's what Wall Street expects from Intellia Therapeutics's earnings
Preview: Intellia Therapeutics's Earnings
NTLA - Intellia Therapeutics, Inc.
3 Small-Cap Biotech Stocks With Positive Momentum
Credit Suisse Remains a Buy on Intellia Therapeutics (NTLA)
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Company Calendar

Last Earnings
8/03/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
598
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.18
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+152.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-474,190,000.00
Net Margins
-854.92%
Pretax Margin
-854.92%

Debt

Sales & Book Value

Annual Sales
$53.04 million
Book Value
$15.70 per share

Miscellaneous

Free Float
85,836,000
Market Cap
$2.81 billion
Optionable
Optionable
Beta
1.84
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. John M. Leonard M.D. (Age 66)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Glenn G. Goddard CPAMr. Glenn G. Goddard CPA (Age 52)
    Exec. VP, CFO & Treasurer
    Comp: $630.91k
  • Dr. Laura Sepp-Lorenzino Ph.D. (Age 62)
    Exec. VP & Chief Scientific Officer
    Comp: $670.58k
  • Mr. James E. Basta Esq. (Age 57)
    J.D., Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $616.15k
  • Dr. David Lebwohl M.D. (Age 68)
    Exec. VP & Chief Medical Officer
    Comp: $671.42k
  • Mr. Derek Hicks (Age 50)
    Exec. VP & Chief Bus. Officer
    Comp: $823.42k
  • Mr. Nessan Bermingham Ph.D. (Age 50)
    Founder & Member of Scientific Advisor Board
  • Dr. Rachel E. Haurwitz Ph.D. (Age 37)
    Co-Founder
  • Dr. Andrew May
    Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna Ph.D. (Age 59)
    Founder & Member of Scientific Advisor Board













NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2023?

18 Wall Street research analysts have issued 1-year target prices for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $40.00 to $120.00. On average, they predict the company's share price to reach $80.18 in the next twelve months. This suggests a possible upside of 152.4% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2023?

Intellia Therapeutics' stock was trading at $34.89 at the beginning of 2023. Since then, NTLA stock has decreased by 9.0% and is now trading at $31.76.
View the best growth stocks for 2023 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its earnings results on Thursday, August, 3rd. The company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by $0.08. The company earned $13.59 million during the quarter, compared to analysts' expectations of $12.08 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 41.64% and a negative net margin of 854.92%. The firm's revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.33) EPS.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $31.76.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $2.81 billion and generates $53.04 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 598 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -